Abiopharma

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BW LPG Enters Into Agreement for Eight 90’cbm Panamax Newbuildings with Hyundai Heavy Industries

Mirum Pharma - Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sportradar Group AG (SRAD) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

CVLT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Commvault Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

GOSS 2-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS